• Deciphera Announces Positive Results from Ripretinib Study americanpharmaceuticalreview
    August 14, 2019
    Deciphera Pharmaceuticals announced positive top-line data from the INVICTUS pivotal Phase 3 clinical study of ripretinib, a broad-spectrum KIT and PDGFRα inhibitor, in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST).
PharmaSources Customer Service